Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312845 · ClinicalTrials.gov registry record · Phase 3
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 3 study of Non-Hodgkin's Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
- 20
- Study locations
NCT00312845: Completed Phase 3 study of Non-Hodgkin's Lymphoma, sponsored by Millennium Pharmaceuticals.
NCT00312845 is a Phase 3 study of Non-Hodgkin's Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 676 participants, above the 211-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (220% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312845, a Phase 3 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.
Primary Outcome
Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Bortezomib + Rituximab
Study Locations (20)
California
- Central Hematology Oncology Medical Group, Inc - Alhambra
- Comprehensive Blood and Cancer Center - Bakersfield
- Providence Saint Joseph Medical Center - Burbank
- St. Jude Heritage Medical Group - Fullerton
- Wilshire Oncology Medical Group, Inc. - La Verne
- Pacific Shores Medical Group - Long Beach
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
- North Valley Hematology Oncology - Mission Hills
- University of California, Irvine Medical Center - Orange
- Ventura County Hematology-Oncology Specialists - Oxnard
- Cancer Care Associates Medical Group, Inc. - Redondo Beach
- Central Coast Medical Oncology Corporation - Santa Maria
Florida
- Integrated Community Oncology Network - Jacksonville
- Innovative Clinical Research of South Florida - Miami
- Palm Beach Cancer Institute - West Palm Beach
Connecticut
- Norwalk Medical Group - Norwalk
- Hematology Oncology PC - Stamford
Alabama
- East Alabama Medical Center - Opelika
Georgia
- Emory Univeersity ,Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
What the finished NCT00312845 record still lists
NCT00312845 is an interventional study that assigns participants to a tested intervention. The registered 676 participants enrollment target is mid-sized for trials with a published cap, above the 211-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (220% higher).
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT00312845 names 20 study sites across 5 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00312845 about?
NCT00312845 is a clinical study titled "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma". The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituxima...
What is the current status of trial NCT00312845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2006-03. Estimated completion is 2010-07.
What conditions does trial NCT00312845 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00312845?
The interventions under investigation include: Rituximab (DRUG), Bortezomib + Rituximab (DRUG).
Who is sponsoring clinical trial NCT00312845?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00312845 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00312845's enrollment target sits among peer trials
676 6th of 63 higher than 58 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
COMPLETED · Phase 3
-
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
COMPLETED · Phase 3
-
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
COMPLETED · Phase 3
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07227337 · 676 participants · NA
Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- NCT05356234 · 675 participants · NA
Ignite Study of the Jewish Family and Children's Service of the Suncoast, Inc.
- NCT06070870 · 675 participants · NA
Health Education Approach to Lung Screening
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia